市場調査レポート

商品コード

1445544

尖圭コンジローマの世界市場の評価：薬剤タイプ・治療法・投与経路・エンドユーザー・地域別の機会および予測 (2017～2031年)

Genital Warts Assessment, By Drug Type, By Treatment, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年03月07日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 221 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 707,130円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 895,698円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,288,548円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の尖圭コンジローマの市場規模は、2024年から2031年の予測期間中にCAGR 4.79％に達し、2023年の20億1,000万米ドルから、2031年には29億2,000万米ドルの規模に成長すると予測されています。

尖圭コンジローマの市場は特に成人におけるHPV感染者数の増加により成長しています。政府の取り組みに加え、技術の進歩やR&D努力も市場を大きく後押ししています。HPVは世界中で人口が急激に増加しており、尖圭コンジローマの症例も増加しています。

尖圭コンジローマの増加

世界でもっとも流行している性病のひとつが、ヒトパピローマウイルス (HPV) による尖圭コンジローマです。ほとんどのHPV感染は良性で自然に治りますが、一部のウイルス株は尖圭コンジローマや数種類の癌を引き起こす可能性があります。尖圭コンジローマを含むHPV関連疾患の有病率の上昇に伴い、診断機器、ワクチン接種、治療法の開発への関心が高まっており、市場は急速に拡大しています。パップスメアやHPV検査による定期的なスクリーニングによって早期発見・早期治療が可能になったため、死亡率は低下しています。感染力の強い尖圭コンジローマは、HPV6株と11株によって引き起こされることが知られています。これらは致命的なものではありませんが、不快感をもたらし、生活の質を低下させます。

技術の進歩

適応検知、治療、予防の向上は昔から医療技術の進歩によって実現されてきました。尖圭コンジローマなどのヒトパピローマウイルス (HPV) に関連する疾患の治療もそれらの分野の一つであり、技術が大きな影響を及ぼしています。近年の尖圭コンジローマの市場を牽引しているのは技術改良の進展です。HPVとそれに関連する疾患を特定する主な手段は、これまではパップスメアとHPV DNA検査とされてきましたが、分子診断や液体ベースの細胞診などの最近の技術も登場しています。液体ベースの細胞診の使用は、異常の同定を容易にしています。

局所治療が世界市場で優位に

治療法別では、局所治療が予測期間中に急成長が見込まれています。局所治療はHPV感染の管理に成功しています。症状だけでなく根本的なウイルスを治療することで、患者に包括的な医学的治療を提供します。これらの治療法は、尖圭コンジローマを破壊し、体の免疫系を刺激してウイルスと闘わせることで効果を発揮します。一般的に使用される局所治療薬には、イミキモド、ポドフィロックス、シネカテキンなどがあります。イミキモドは、ウイルスを攻撃するために身体の免疫系を刺激する免疫応答調節薬であり、患部に直接塗布します。

当レポートでは、世界の尖圭コンジローマの市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場規模・予測
薬剤の種類別
- イミキモド
- ポドフィリン・ポドフィロックス
- トリクロロ酢酸
- シンカテキン
- イソトレチノイン
- その他
治療法別
- 凍結療法
- レーザー除去
- 外科的切除
- 局所治療
投与経路別
- 経口
- 非経口
エンドユーザー別
- 病院
- 皮膚科センター
- 研究センター
- その他
地域別
- 北米
- 欧州
- アジア太平洋
- 南米
- 中東・アフリカ
企業別市場シェア

第5章世界の尖圭コンジローマ市場の展望：地域別

北米
欧州
アジア太平洋
南米
中東・アフリカ

第6章市場マッピング

薬剤タイプ別
投与経路別
治療法別
エンドユーザー別
地域別

第7章マクロ環境と産業構造

需要供給分析
輸出入分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長抑制要因（課題、抑制要因）

第9章規制の枠組みとイノベーション

臨床試験
特許の情勢
規制当局の承認
イノベーション/新興技術

第10章主要企業の情勢

市場リーダー上位5社の競合マトリックス
市場リーダー上位5社の市場収益分析
M&A・ジョイントベンチャー (該当する場合)
SWOT分析 (参入5社)
特許分析 (該当する場合)

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

Pfizer Inc.
Sanofi-Aventis LLC
Orgenesis Biotech Company
Teva Pharmaceutical Industries Ltd.
Verrica Pharmaceuticals
Merck & Co., Inc
Cipla Ltd.
GlaxoSmithKline Plc
Phio Pharmaceuticals Corp.
Taro Pharmaceutical Industries Ltd.
Mylan N.V.
Bausch Health Companies, Inc.

第14章戦略的提言

第14章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 3. Global Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 4. Global Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 5. Global Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 6. Global Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 7. Global Genital Warts Market Share (%), By Region, 2017-2031F
Figure 8. North America Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 9. North America Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 10. North America Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 11. North America Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 12. North America Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 13. North America Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 14. North America Genital Warts Market Share (%), By Country, 2017-2031F
Figure 15. United States Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 16. United States Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 17. United States Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 18. United States Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 19. United States Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 20. United States Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 21. Canada Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 22. Canada Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 23. Canada Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 24. Canada Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 25. Canada Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 26. Canada Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 27. Mexico Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 28. Mexico Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 29. Mexico Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 30. Mexico Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 31. Mexico Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 32. Mexico Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 33. Europe Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 34. Europe Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 35. Europe Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 36. Europe Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 37. Europe Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 38. Europe Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 39. Europe Genital Warts Market Share (%), By Country, 2017-2031F
Figure 40. Germany Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 41. Germany Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 42. Germany Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 43. Germany Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 44. Germany Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 45. Germany Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 46. France Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 47. France Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 48. France Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 49. France Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 50. France Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 51. France Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 52. Italy Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 53. Italy Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 54. Italy Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 55. Italy Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 56. Italy Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 57. Italy Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 58. United Kingdom Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 59. United Kingdom Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 60. United Kingdom Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 61. United Kingdom Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 62. United Kingdom Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 63. United Kingdom Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 64. Russia Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 65. Russia Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 66. Russia Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 67. Russia Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 68. Russia Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 69. Russia Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 70. Netherlands Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 71. Netherlands Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 72. Netherlands Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 73. Netherlands Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 74. Netherlands Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 75. Netherlands Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 76. Spain Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 77. Spain Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 78. Spain Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 79. Spain Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 80. Spain Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 81. Spain Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 82. Turkey Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 83. Turkey Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 84. Turkey Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 85. Turkey Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 86. Turkey Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 87. Turkey Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 88. Poland Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 89. Poland Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 90. Poland Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 91. Poland Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 92. Poland Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 93. Poland Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 94. South America Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 95. South America Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 96. South America Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 97. South America Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 98. South America Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 99. South America Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 100. South America Genital Warts Market Share (%), By Country, 2017-2031F
Figure 101. Brazil Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 102. Brazil Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 103. Brazil Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 104. Brazil Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 105. Brazil Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 106. Brazil Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 107. Argentina Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 108. Argentina Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 109. Argentina Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 110. Argentina Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 111. Argentina Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 112. Argentina Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 113. Asia-Pacific Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 114. Asia-Pacific Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 115. Asia-Pacific Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 116. Asia-Pacific Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 117. Asia-Pacific Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 118. Asia-Pacific Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 119. Asia-Pacific Genital Warts Market Share (%), By Country, 2017-2031F
Figure 120. India Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 121. India Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 122. India Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 123. India Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 124. India Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 125. India Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 126. China Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 127. China Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 128. China Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 129. China Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 130. China Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 131. China Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 132. Japan Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 133. Japan Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 134. Japan Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 135. Japan Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 136. Japan Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 137. Japan Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 138. Australia Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 139. Australia Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 140. Australia Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 141. Australia Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 142. Australia Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 143. Australia Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 144. Vietnam Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 145. Vietnam Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 146. Vietnam Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 147. Vietnam Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 148. Vietnam Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 149. Vietnam Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 150. South Korea Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 151. South Korea Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 152. South Korea Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 153. South Korea Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 154. South Korea Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 155. South Korea Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 156. Indonesia Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 157. Indonesia Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 158. Indonesia Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 159. Indonesia Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 160. Indonesia Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 161. Indonesia Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 162. Philippines Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 163. Philippines Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 164. Philippines Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 165. Philippines Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 166. Philippines Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 167. Philippines Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 168. Middle East & Africa Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 169. Middle East & Africa Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 170. Middle East & Africa Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 171. Middle East & Africa Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 172. Middle East & Africa Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 173. Middle East & Africa Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 174. Middle East & Africa Genital Warts Market Share (%), By Country, 2017-2031F
Figure 175. Saudi Arabia Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 176. Saudi Arabia Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 177. Saudi Arabia Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 178. Saudi Arabia Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 179. Saudi Arabia Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 180. Saudi Arabia Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 181. UAE Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 182. UAE Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 183. UAE Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 184. UAE Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 185. UAE Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 186. UAE Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 187. South Africa Genital Warts Market, By Value, In USD Billion, 2017-2031F
Figure 188. South Africa Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
Figure 189. South Africa Genital Warts Market Share (%), By Drug Type, 2017-2031F
Figure 190. South Africa Genital Warts Market Share (%), By Treatment, 2017-2031F
Figure 191. South Africa Genital Warts Market Share (%), By Route of Administration, 2017-2031F
Figure 192. South Africa Genital Warts Market Share (%), By End-user, 2017-2031F
Figure 193. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 194. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 195. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11093

Global genital warts market is projected to witness a CAGR of 4.79% during the forecast period 2024-2031, growing from USD 2.01 billion in 2023 to USD 2.92 billion in 2031. The genital warts market is experiencing growth due to rising numbers of HPV cases, particularly in adults. In addition to government initiatives, advancing technology and efforts of R&D are also fueling the market greatly. HPV is seen to drastically rise in population all over the globe, leading to a rise in several genital warts cases as well. Technology is also advancing in terms of improved solutions to disease. The vaccine for HPV gives the body enough immunization to not let warts or other such STDs happen. The government is playing a major role in spreading awareness about getting vaccinations to avoid getting such diseases in the first place. Giving free vaccines in schools, and camps, and organizing rallies and camps to spread awareness are some of the government initiatives, which are offering lucrative market opportunities.

In Canada, a statement was passed by the Minister of Health, the Minister of Mental Health and Addictions, and the Associate Minister of Health on Human Papillomavirus Prevention Week. It stated that vaccination is one of the best methods to avoid cancer and genital warts. The HPV vaccination is available at no cost through school-based clinics, public health clinics, or catch-up programs. It is advised for 9 to 14-year-olds as part of their usual vaccination schedule.

The efforts underway to reach the national goal of 90% immunization among Canadian youth by 2025 are heartening. 84% of 14-year-olds received an HPV vaccination in 2021, a considerable increase in males' HPV vaccination rates over the two years prior. Even if this objective can be attained, it is crucial to keep advocating for and supporting HPV vaccination for all kids.

Increasing Prevalence of Genital Warts

Throughout the world, one of the most prevalent STDs is the genital warts caused due to human papillomavirus (HPV). While most HPV infections are benign and go away on their own, some virus strains can cause genital warts and several kinds of cancer. The global market for genital warts is expanding rapidly because of the growing interest in the creation of diagnostic instruments, vaccinations, and therapies due to the rising prevalence of HPV-related illnesses, including genital warts. Mortality rates have decreased because of early discovery and treatment made possible by routine screening with Pap smears and HPV testing. Highly contagious genital warts are known to be caused by HPV strains 6 and 11. They may not be fatal, but they can cause discomfort and reduce one's quality of life. The market for associated disorders with HPV, such as genital warts, is expected to increase significantly in the future as creative approaches to treating HPV-related illnesses become more and more in demand. There is hope that we may reduce the prevalence of such diseases and improve people's general health and well-being globally through ongoing research, immunization campaigns, and public awareness initiatives.

According to a study that was published in 2023 by The Lancet Global Health, nearly one in three men over the age of 15 have at least one genital human papillomavirus (HPV) type infection, and one in five have one or more of the high risks, or oncogenic, HPV kinds. These estimates highlight the significance of collaborative efforts to manage HPV infection and reduce the prevalence of HPV-related disease in both men and women. Such efforts are anticipated to increase market demand.

Technological Advancements

Better indication detection, treatment, and prevention have long been made possible by technological improvements in the healthcare sector. One such field is the treatment of diseases linked to the human papillomavirus (HPV), such as genital warts, where technology is having a big influence. Growing technological improvements have been a major factor in driving the global genital warts market in recent years. Developing more precise and accessible screening methods is one of the main ways that technology improvements are impacting the genital warts business. The main tools for identifying HPV and the disease associated with it have historically been Pap smears and HPV DNA testing. But more recent technologies have also surfaced, like molecular diagnostics and liquid-based cytology. The use of liquid-based cytology facilitates the identification of anomalies.

Conversely, molecular testing finds the virus' genetic makeup and yields more accurate results. These advanced screening techniques not only increase diagnosis accuracy, but also provide faster results. The development of vaccinations that specifically target HPV strains has been made possible by developments in molecular biology and genetic sequencing. The development of the HPV vaccination has revolutionized the fight against cervical cancer, genital warts, and other related conditions. The goal of ongoing research and development is to increase the effectiveness of vaccines and increase their use.

Teva Pharmaceuticals launched the first generic version of Absorica (isotretinoin) in April 2021, intended to treat severe, resistant nodular acne genital warts. Oral isotretinoin is an effective therapy option for patients with resistant facial plane genital warts.

Topical Treatment Method is Dominating the Global Market

Over the course of the projection period, the topical treatment segment is expected to grow at a rapid rate. Topical treatment is successful in managing HPV infections. They provide patients with an all-encompassing approach to medical therapy by treating the underlying virus as well as the symptoms. These treatments work by destroying the warts and stimulating the body's immune system to fight the virus. Some commonly used topical treatments include imiquimod, podofilox, and sinecatechins. Imiquimod is an immune response modifier that stimulates the body's immune system to attack the virus and is applied directly to the affected area.

In March 2020, Verrica Pharmaceuticals Inc. and Torii Pharmaceutical Co., Ltd. announced a collaboration and licensing agreement to create and commercialize product candidates, such as VP-102, for a topical cantharidin formulation intended to treat molluscum contagiosum and common genital warts in Japan.

North America to Dominate Genital Warts Market

With the biggest market share in terms of value, North America has emerged as the leading force in the global genital warts industry. The high incidence of HPV in the region is one of the main causes of North America's market domination in genital warts. Particularly in the United States, there is a significant HPV burden, with millions of new cases reported yearly. Due to the high prevalence, there is a sizable market for HPV-related goods and services due to the increasing demand for HPV diagnostic tests, vaccinations, and treatment options. Modern hospitals, cutting-edge diagnostic tools, and a highly qualified medical workforce are all part of North America's well-developed healthcare infrastructure. Efficient screening, diagnosis, and treatment of illnesses linked to HPV are made possible by this infrastructure. Moreover, with the state-of-the-art medical treatments and technologies, North America is the top choice for patients looking for HPV-related healthcare services that may include treatment of genital warts, cervical cancer, etc. According to the estimate by the Wahington State Department of Health, the prevalence of genital HPV is becoming more and more common, with 14 million newly Americans contracting the virus annually and 79 million Americans currently suffering from HPV infection.

Future Market Scenario (2024 - 2031F)

The growing need to address a variety of symptoms that occur due to the HPV strains, especially genital warts, is driving the market growth. With the advent of new and improved technologies and well researched new drugs and vaccines that are available to everyone, the market will surely see expansion. Treatments like that of laser and surgery are also growing in popularity. They are expensive but because they provide quicker and better results, people are opting for laser despite its high cost. Global healthcare governing bodies are also launching several awareness campaigns to increase awareness related to genital warts among the general population in emerging countries, which, in turn, is acting as a significant market trend.

Key Players Landscape and Outlook

The global genital warts market is dominated by a few major players. Among the businesses that are presently governing the market shares are Pfizer Inc., Sanofi, Orgenesis biotech company, Teva Pharmaceutical Industries Ltd., Verrica Pharmaceuticals, Merck & Co., Inc, and Cipla Ltd. These companies are dominating the market due to their persistent efforts towards R&D, technological advancements, and reliable quality.

Affinivax, Inc. is a diagnostic biopharmaceutical firm based in Cambridge, Massachusetts. GSK plc agreed to buy it in May 2022 for a cash price of $2.1 billion, with an extra $1.2 billion possible if certain growth goals are met. Leading the charge in creating a cutting-edge pneumococcal vaccination for the future is Affinivax.

Eli Lilly and UNICEF signed a new partnership in September 2021 with the goal of improving health outcomes for 10 million children and adolescents with serious non-communicable diseases (NCDs) by 2025. Lilly has pledged $14.4 million as part of this cooperation to support UNICEF's ongoing initiatives in particular nations targeted at reducing NCD risk factors.

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Genital Warts Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. By Value
- 4.1.2. By Volume
4.2. By Drug Type
- 4.2.1. Imiquimod
- 4.2.2. Podophyllin and Podofilox
- 4.2.3. Trichloroacetic acid
- 4.2.4. Sine catechins
- 4.2.5. Isotretinoin
- 4.2.6. Others
4.3. By Treatment
- 4.3.1. Cryotherapy
- 4.3.2. Laser removal
- 4.3.3. Surgical removal
- 4.3.4. Topical treatment
4.4. By Route of Administration
- 4.4.1. Oral
- 4.4.2. Parenteral
4.5. By End-user
- 4.5.1. Hospitals
- 4.5.2. Dermatology Centers
- 4.5.3. Research Centers
- 4.5.4. Others
4.6. By Region
- 4.6.1. North America
- 4.6.2. Europe
- 4.6.3. Asia-Pacific
- 4.6.4. South America
- 4.6.5. Middle East and Africa
4.7. By Company Market Share (%), 2023

5. Global Genital Warts Market Outlook, By Region, 2017-2031F

5.1. North America*
- 5.1.1. Market Size & Forecast
  - 5.1.1.1. By Value
  - 5.1.1.2. By Volume
- 5.1.2. By Drug Type
  - 5.1.2.1. Imiquimod
  - 5.1.2.2. Podophyllin and Podofilox
  - 5.1.2.3. Trichloroacetic acid
  - 5.1.2.4. Sine catechins
  - 5.1.2.5. Isotretinoin
  - 5.1.2.6. Others
- 5.1.3. By Treatment
  - 5.1.3.1. Cryotherapy
  - 5.1.3.2. Laser removal
  - 5.1.3.3. Surgical removal
  - 5.1.3.4. Topical treatment
- 5.1.4. By Route of Administration
  - 5.1.4.1. Oral
  - 5.1.4.2. Parenteral
- 5.1.5. By End-user
  - 5.1.5.1. Hospitals
  - 5.1.5.2. Dermatology Centers
  - 5.1.5.3. Research Centers
  - 5.1.5.4. Others
- 5.1.6. United States*
  - 5.1.6.1. Market Size & Forecast
  - 5.1.6.1.1. By Value
  - 5.1.6.1.2. By Volume
  - 5.1.6.2. By Drug Type
  - 5.1.6.2.1. Imiquimod
  - 5.1.6.2.2. Podophyllin and Podofilox
  - 5.1.6.2.3. Trichloroacetic acid
  - 5.1.6.2.4. Sine catechins
  - 5.1.6.2.5. Isotretinoin
  - 5.1.6.2.6. Others
  - 5.1.6.3. By Treatment
  - 5.1.6.3.1. Cryotherapy
  - 5.1.6.3.2. Laser removal
  - 5.1.6.3.3. Surgical removal
  - 5.1.6.3.4. Topical treatment
  - 5.1.6.4. By Route of Administration
  - 5.1.6.4.1. Oral
  - 5.1.6.4.2. Parenteral
  - 5.1.6.5. By End-user
  - 5.1.6.5.1. Hospitals
  - 5.1.6.5.2. Dermatology Centers
  - 5.1.6.5.3. Research Centers
  - 5.1.6.5.4. Others
- 5.1.7. Canada
- 5.1.8. Mexico

All segments will be provided for all regions and countries covered

5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
5.3. Asia-Pacific
- 5.3.1. India
- 5.3.2. China
- 5.3.3. Japan
- 5.3.4. Australia
- 5.3.5. Vietnam
- 5.3.6. South Korea
- 5.3.7. Indonesia
- 5.3.8. Philippines
5.4. South America
- 5.4.1. Brazil
- 5.4.2. Argentina
5.5. Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa

6. Market Mapping, 2023

6.1. By Drug Type
6.2. By Route of Administration
6.3. By Treatment
6.4. By End-user
6.5. By Region

7. Macro Environment and Industry Structure

7.1. Demand Supply Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. Pfizer Inc.
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products & Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus & Geographical Presence
- 13.1.6. Recent Developments
13.2. Sanofi-Aventis LLC
13.3. Orgenesis Biotech Company
13.4. Teva Pharmaceutical Industries Ltd.
13.5. Verrica Pharmaceuticals
13.6. Merck & Co., Inc
13.7. Cipla Ltd.
13.8. GlaxoSmithKline Plc
13.9. Phio Pharmaceuticals Corp.
13.10. Taro Pharmaceutical Industries Ltd.
13.11. Mylan N.V.
13.12. Bausch Health Companies, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

尖圭コンジローマの世界市場の評価：薬剤タイプ・治療法・投与経路・エンドユーザー・地域別の機会および予測 (2017～2031年)

Genital Warts Assessment, By Drug Type, By Treatment, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の尖圭コンジローマ市場の展望

第5章世界の尖圭コンジローマ市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第14章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Genital Warts Market Outlook, 2017-2031F

5. Global Genital Warts Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

尖圭コンジローマの世界市場の評価：薬剤タイプ・治療法・投与経路・エンドユーザー・地域別の機会および予測 (2017～2031年)

Genital Warts Assessment, By Drug Type, By Treatment, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の尖圭コンジローマ市場の展望

第5章 世界の尖圭コンジローマ市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第14章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Genital Warts Market Outlook, 2017-2031F

5. Global Genital Warts Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の尖圭コンジローマ市場の展望

第5章世界の尖圭コンジローマ市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第14章当社について・免責事項